Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Stelara-associated Cardiovascular Events: Emerging Drug Safety Issue

October 29, 2020 By Law Offices of Thomas J. Lamb, P.A.

There is a new drug safety issue for Stelara. This time it is that Stelara-associated cardiovascular events were reported in a French medical study which, in turn, has resulted in some concern about the safety of Stelara. The Stelara French study results were outlined in this medical journal article, "Association Between Early Severe … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, cardiovascular events, Stelara

Possible Public Health Issue For Hemlibra Used By Hemophilia A Patients

December 16, 2019 By Law Offices of Thomas J. Lamb, P.A.

Hemlibra (emicizumab) is used to prevent or reduce the frequency of bleeding episodes in hemophilia A patients. Hemlibra was initially approved by the FDA in 2017.  In November 2019, however, some drug safety issues involving Hemlibra were pointed out. From this letter-to-the-editor piece, “Deaths Associated with Emicizumab in Patients with … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, heart-related deaths

Uloric Increased Risk of Patient Cardiovascular Deaths, Says Health Canada

November 15, 2019 By Law Offices of Thomas J. Lamb, P.A.

Based on the results of the CARES study, Health Canada mandated an Uloric label change in early November 2019 which warns about an increased risk of Uloric-related cardiovascular deaths. Uloric is now only approved for use in Canada as a treatment “to lower serum uric acid levels in patients with gout who have an inadequate response or intolerance … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, Uloric

Imbruvica Cardiovascular Adverse Drug Reactions Soon After Administration

October 18, 2019 By Law Offices of Thomas J. Lamb, P.A.

A medical journal article published by the Journal of the American College of Cardiology in October 2018 reports that Imbruvica cardiovascular adverse drug reactions often occurred soon after the administration of Imbruvica. In summary, patients treated with Imbruvica had an increased occurrence of severe and sometimes fatal cardiac events, with … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, Imbruvica

Xeljanz FDA Drug Safety Communication About Increased Risks of Blood Clots And Death

August 8, 2019 By Law Offices of Thomas J. Lamb, P.A.

This Xeljanz FDA Drug Safety Communication was issued July 26, 2019: “FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)”. From that document we get the following information: The U.S. Food and Drug Administration has approved new … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blood clots, Cardiovascular death, heart-related deaths, Xeljanz

Xeljanz Safety Concerns and New Precautions

August 6, 2019 By Law Offices of Thomas J. Lamb, P.A.

You may have read our previous articles about Xeljanz and its risk of leading to Pulmonary Embolism or even death.  In June, we posted "Xeljanz Related Blood Clots Can Cause Pulmonary Embolism (PE) Or Deep Vein Thrombosis (DVT) With Patient Deaths Possible" that provides information on the serious side effects found out through a post-marketing … [Read more...]

Filed Under: Unsafe Drugs Tagged With: black-box drug label warning, blood clots, Cardiovascular death, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Xeljanz

Uloric Warning: Avoid Uloric If Prior Myocardial Infarction, Stroke, Or Unstable Angina

August 5, 2019 By Law Offices of Thomas J. Lamb, P.A.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a Uloric warning in July 2019 stating that patients with prior myocardial infarction, stroke, or unstable angina should avoid Uloric as there is a higher risk of death. From this July 2019 MHRA Drug Safety Update, “Febuxostat (Adenuric): increased risk of … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, Myocardial Infarctions (MI), Strokes, Uloric

Uloric Lawsuits Follow Recent FDA Warnings About Heart-Related Deaths And Side Effects

May 1, 2019 By Law Offices of Thomas J. Lamb, P.A.

Following recent FDA-mandated label changes, there have been Uloric lawsuits filed against Takeda Pharmaceuticals America, Inc., the manufacturer of Uloric. Uloric (febuxostat) tablets have been generally prescribed for the management of chronic gout since 2009. In February 2019 the FDA required its strongest safety warning, i.e., Bolded … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, Heart Attacks, Strokes, Uloric

Xeljanz Used For Ulcerative Colitis May Increase Risk Of Pulmonary Embolism

February 26, 2019 By Law Offices of Thomas J. Lamb, P.A.

There appears to be a new Xeljanz drug-safety problem for patients with ulcerative colitis (UC) who use the 10 mg twice daily recommended dosage of Xeljanz. In a February 20, 2019 Endpoints News article written by John Carroll, “Pfizer drops 10 mg dose of best-selling Xeljanz as study spotlights cardio safety issue, higher rate of deaths”: One … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, cardiovascular events, Pulmonary Embolism (PE), Xeljanz

Uloric Recall Discussed By FDA Advisory Committees In January 2019

January 25, 2019 By Law Offices of Thomas J. Lamb, P.A.

On January 10, 2019 the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee panelists discussed the potential biological mechanisms behind cardiovascular (CV) events associated with Uloric (febuxostat) use. From this January 11, 2019 MedPage Today report, “Make Uloric Second-Line for Gout, FDA Advisors Say”, … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, cardiovascular events, Uloric

  • 1
  • 2
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.